ESC 2022: Kidney disease patients with coronary disease see no improvement in survival at five years with an invasive approach

679
Sripal Bangalore (right) at ESC 2022

In patients with advanced chronic kidney disease (CKD) and chronic coronary disease, an invasive strategy involving percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG) does not reduce the five-year risk of death compared to a conservative strategy.

These were findings of the ISCHEMIA-CKD EXTEND trial, presented during a hot line session on the final morning of the European Society of Cardiology (ESC) annual congress (26–29 August, Barcelona, Spain). Sripal Bangalore (New York University School of Medicine, New York, USA) delivered the interim, five-year findings.

Previous trials of an invasive versus conservative strategy for the management of chronic coronary disease have excluded patients with advanced CKD or included only a small proportion of these patients. Therefore, the optimal management of this high-risk group of patients is unknown.

The primary results of the ISCHEMIA-CKD trial have been previously reported. The trial enrolled 777 patients with advanced chronic kidney disease (defined as estimated glomerular filtration rate <30 ml/min/1.73 m2 or on dialysis) and moderate or severe ischaemia on stress testing. The median age of participants was 63 years and 31% were women.

Patients were randomly allocated to either an initial invasive strategy, which consisted of cardiac catheterisation and optimal revascularisation with PCI or CABG, if suitable, plus guideline directed medical therapy, versus an initial conservative strategy of guideline directed medical therapy alone, with cardiac catheterisation and revascularisation with PCI or CABG, if suitable, reserved for failure of medical therapy. At a median follow up of 2.2 years, the initial invasive strategy did not reduce the primary outcome of death or nonfatal myocardial infarction.

ISCHEMIA-CKD EXTEND is following up trial participants for a median of nine years. The results of an interim analysis at five years are reported today. The analysis included all 777 patients from the trial. The primary endpoint was all-cause death and the secondary endpoints were cardiovascular death and non-cardiovascular death.

Commenting on the results, Bangalore said: “In this five year follow up of patients from the ISCHEMIA-CKD trial, an initial invasive management strategy did not improve survival when added to guideline directed medical therapy in patients with advanced chronic kidney disease and chronic coronary disease. Similarly, there were no significant differences in cardiovascular death or non-cardiovascular death with an invasive versus conservative strategy.

“Further analyses showed no significant heterogeneity of treatment effect for any subgroup. Of note, the death rate was very high with close to 40% mortality at five years indicating a very high-risk group of patients who are in urgent need of therapies to reduce this risk.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here